147 related articles for article (PubMed ID: 37902743)
1. Aiming for the Best Glycemic Control Beyond Time in Range: Time in Tight Range as a New Continuous Glucose Monitoring Metric in Children and Adolescents with Type 1 Diabetes Using Different Treatment Modalities.
Passanisi S; Piona C; Salzano G; Marigliano M; Bombaci B; Morandi A; Alibrandi A; Maffeis C; Lombardo F
Diabetes Technol Ther; 2024 Mar; 26(3):161-166. PubMed ID: 37902743
[No Abstract] [Full Text] [Related]
2. Time In Tight Range in children and adolescents with type 1 diabetes: A cross-sectional observational single centre study evaluating efficacy of new advanced technologies.
Schiaffini R; Lumaca A; Martino M; Rapini N; Deodati A; Amodeo ME; Ciampalini P; Matteoli MC; Pampanini V; Cianfarani S
Diabetes Metab Res Rev; 2024 Jul; 40(5):e3826. PubMed ID: 38824455
[TBL] [Abstract][Full Text] [Related]
3. Is It Time to Move Beyond TIR to TITR? Real-World Data from Over 20,000 Users of Continuous Glucose Monitoring in Patients with Type 1 and Type 2 Diabetes.
Dunn TC; Ajjan RA; Bergenstal RM; Xu Y
Diabetes Technol Ther; 2024 Mar; 26(3):203-210. PubMed ID: 38444315
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of Continuous Glucose Monitoring-Measured Time-in-Range 70-180 mg/dL Versus Time-in-Tight-Range 70-140 mg/dL.
Beck RW; Raghinaru D; Calhoun P; Bergenstal RM
Diabetes Technol Ther; 2024 Mar; 26(3):151-155. PubMed ID: 37870460
[No Abstract] [Full Text] [Related]
5. Glycemic Control by Treatment Modalities: National Registry-Based Population Data in Children and Adolescents with Type 1 Diabetes.
Šumnik Z; Pavlíková M; Neuman V; Petruželková L; Konečná P; Venháčová P; Škvor J; Pomahačová R; Neumann D; Vosáhlo J; Strnadel J; Kocourková K; Obermannová B; Šantová A; Plachý L; Průhová S; Cinek O;
Horm Res Paediatr; 2024; 97(1):70-79. PubMed ID: 37100041
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes with different technology modalities in type 1 diabetes.
Beato-Víbora PI; Gallego-Gamero F; Ambrojo-López A
Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1845-1850. PubMed ID: 33838993
[TBL] [Abstract][Full Text] [Related]
7. Time In Range in Children with Type 1 Diabetes Using Treatment Strategies Based on Nonautomated Insulin Delivery Systems in the Real World.
Cherubini V; Bonfanti R; Casertano A; De Nitto E; Iannilli A; Lombardo F; Maltoni G; Marigliano M; Bassi M; Minuto N; Mozzillo E; Rabbone I; Rapini N; Rigamonti A; Salzano G; Scaramuzza A; Schiaffini R; Tinti D; Toni S; Zagaroli L; Zucchini S; Maffeis C; Gesuita R
Diabetes Technol Ther; 2020 Jul; 22(7):509-515. PubMed ID: 32073311
[No Abstract] [Full Text] [Related]
8. Glycemic Control in Relation to Technology Use in a Single-Center Cohort of Children with Type 1 Diabetes.
Sawyer A; Sobczak M; Forlenza GP; Alonso GT
Diabetes Technol Ther; 2022 Jun; 24(6):409-415. PubMed ID: 35099306
[No Abstract] [Full Text] [Related]
9. Glycemic, maternal and neonatal outcomes in women with type 1 diabetes using continuous glucose monitoring during pregnancy - Pump vs multiple daily injections, a secondary analysis of an observational cohort study.
Kjölhede K; Berntorp K; Kristensen K; Katsarou A; Shaat N; Wiberg N; Knop FK; Kristensen L; Dotevall A; Elfvin A; Sandgren U; Sengpiel V; Englund-Ögge L
Acta Obstet Gynecol Scand; 2021 May; 100(5):927-933. PubMed ID: 33176006
[TBL] [Abstract][Full Text] [Related]
10. Effect of a Hybrid Closed-Loop System on Glycemic and Psychosocial Outcomes in Children and Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
Abraham MB; de Bock M; Smith GJ; Dart J; Fairchild JM; King BR; Ambler GR; Cameron FJ; McAuley SA; Keech AC; Jenkins A; Davis EA; O'Neal DN; Jones TW;
JAMA Pediatr; 2021 Dec; 175(12):1227-1235. PubMed ID: 34633418
[TBL] [Abstract][Full Text] [Related]
11. Evaluating Glucose Control With a Novel Composite Continuous Glucose Monitoring Index.
Leelarathna L; Thabit H; Wilinska ME; Bally L; Mader JK; Pieber TR; Benesch C; Arnolds S; Johnson T; Heinemann L; Hermanns N; Evans ML; Hovorka R
J Diabetes Sci Technol; 2020 Mar; 14(2):277-283. PubMed ID: 30931606
[TBL] [Abstract][Full Text] [Related]
12. Association of Achieving Time in Range Clinical Targets With Treatment Modality Among Youths With Type 1 Diabetes.
Dovc K; Lanzinger S; Cardona-Hernandez R; Tauschmann M; Marigliano M; Cherubini V; Preikša R; Schierloh U; Clapin H; AlJaser F; Pelicand J; Shukla R; Biester T
JAMA Netw Open; 2023 Feb; 6(2):e230077. PubMed ID: 36808243
[TBL] [Abstract][Full Text] [Related]
13. Comparing the effectiveness of continuous subcutaneous insulin infusion with multiple daily insulin injection for patients with type 1 diabetes mellitus evaluated by retrospective continuous glucose monitoring: A real-world data analysis.
Keyu G; Jiaqi L; Liyin Z; Jianan Y; Li F; Zhiyi D; Qin Z; Xia L; Lin Y; Zhiguang Z
Front Public Health; 2022; 10():990281. PubMed ID: 36091534
[TBL] [Abstract][Full Text] [Related]
14. Glucose Monitoring Metrics in Individuals With Type 1 Diabetes Using Different Treatment Modalities: A Real-World Observational Study.
Nørgaard K; Ranjan AG; Laugesen C; Tidemand KG; Green A; Selmer C; Svensson J; Andersen HU; Vistisen D; Carstensen B
Diabetes Care; 2023 Nov; 46(11):1958-1964. PubMed ID: 37610784
[TBL] [Abstract][Full Text] [Related]
15. Glycemia Risk Index as a Novel Metric to Evaluate the Safety of Glycemic Control in Children and Adolescents with Type 1 Diabetes: An Observational, Multicenter, Real-Life Cohort Study.
Piona C; Marigliano M; Roncarà C; Mozzillo E; Di Candia F; Zanfardino A; Iafusco D; Maltoni G; Zucchini S; Piccinno E; Delvecchio M; Passanisi S; Lombardo F; Bonfanti R; Maffeis C
Diabetes Technol Ther; 2023 Jul; 25(7):507-512. PubMed ID: 37155332
[TBL] [Abstract][Full Text] [Related]
16. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes.
Petrovski G; Al Khalaf F; Campbell J; Umer F; Almajaly D; Hamdan M; Hussain K
Acta Diabetol; 2021 Feb; 58(2):207-213. PubMed ID: 33044604
[TBL] [Abstract][Full Text] [Related]
17. During an 18-month course of automated insulin delivery treatment, children aged 2 to 6 years achieve and maintain a higher time in tight range.
Pulkkinen MA; Varimo TJ; Hakonen ET; Hero MT; Miettinen PJ; Tuomaala AK
Diabetes Obes Metab; 2024 Jun; 26(6):2431-2438. PubMed ID: 38514384
[TBL] [Abstract][Full Text] [Related]
18. Time in Tight Glucose Range in Type 1 Diabetes: Predictive Factors and Achievable Targets in Real-World Users of the MiniMed 780G System.
Castañeda J; Arrieta A; van den Heuvel T; Battelino T; Cohen O
Diabetes Care; 2024 May; 47(5):790-797. PubMed ID: 38113453
[TBL] [Abstract][Full Text] [Related]
19. Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States.
Thrasher JR; Arrieta A; Niu F; Cameron KR; Cordero TL; Shin J; Rhinehart AS; Vigersky RA
Diabetes Technol Ther; 2024 Mar; 26(S3):24-31. PubMed ID: 38377317
[No Abstract] [Full Text] [Related]
20. Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections.
McAuley SA; Vogrin S; Lee MH; Paldus B; Trawley S; de Bock MI; Abraham MB; Bach LA; Burt MG; Cohen ND; Colman PG; Davis EA; Hendrieckx C; Holmes-Walker DJ; Jenkins AJ; Kaye J; Keech AC; Kumareswaran K; MacIsaac RJ; McCallum RW; Sims CM; Speight J; Stranks SN; Sundararajan V; Ward GM; Jones TW; O'Neal DN;
Diabetes Technol Ther; 2021 Jun; 23(6):460-466. PubMed ID: 33351699
[No Abstract] [Full Text] [Related]
[Next] [New Search]
